Format

Send to:

Choose Destination
See comment in PubMed Commons below
NMR Biomed. 2006 Oct;19(6):690-701.

MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases.

Author information

  • 1Department of Diagnostic Radiology, Yale University, School of Medicine, 300 Cedar St, New Haven, CT 06520-8043, USA. graeme.mason@yale.edu

Abstract

Magnetic resonance spectroscopy (MRS) is likely in the near future to play a key role in the process of drug discovery and evaluation. As the pharmaceutical industry seeks biochemical markers of drug delivery, efficacy and toxicity, this non-invasive technique offers numerous ways to study adults and children repeatedly and without ionizing radiation. In this article, we survey an array of the information that MRS offers about neurochemistry in general and psychiatric disorders and their treatment in particular. We also present growing evidence of glial abnormalities in neuropsychiatric disorders and discuss what MRS is contributing to that line of investigation. The third major direction of this article is the discussion of where MRS techniques are headed and how those new techniques can contribute to studies of mechanisms of psychiatric disease and drug discovery.

Copyright 2006 John Wiley & Sons, Ltd.

PMID:
16986118
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk